Cue Biopharma Inc (CUE) News

Form 424B5 - Prospectus [Rule 424(b)(5)]

Cue Biopharma Announces Proposed Public Offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Form DEF 14A - Other definitive proxy statements

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference

BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Form PRE 14A - Other preliminary proxy statements

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements

Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while...

Form 8-K - Current report